Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of AG-881 on Lamotrigine PK in Healthy Adults
NCT04015687Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Jul 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vorasidenib in IDH-mutant glioma (3 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Area under the Concentration-time Curve from Time 0 to Infinity, Maximum Observed Plasma Concentration and 6 more. Started Jul 2019; status: completed.
02
Drugs
vorasidenib
03
Conditions
IDH-mutant glioma
Beyond the preview
Go deeper on NCT04015687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04015687.